Related Experiment Videos
Neoepitopes as biomarkers of cartilage catabolism
A J Fosang1, H Stanton, C B Little
1University of Melbourne, Department of Paediatrics, Royal Children's Hospital, Parkville, VIC, Australia.
Abstract:
Progressive degradation of articular cartilage is a central feature of arthritis and a major determinant of long term joint dysfunction. There are no treatments able to halt the progression of cartilage destruction presently available, and monitoring the benefit of potential therapies is hampered by our inability to measure the "health" of articular cartilage. Serial radiographic assessment of joint space narrowing, the current gold standard, requires measurements over a prolonged time (1-5 years) and is prone to technical difficulties. Other strategies for evaluating cartilage degradation are needed to enable both short and long term monitoring of disease progression and response to therapy. One avenue that holds promise is the use of biomarkers that accurately reflect the degradative state of the articular cartilage. Antibodies that recognise terminal amino acid sequences generated by proteolysis at specific sites in the core protein of both aggrecan and type II collagen (neoepitope antibodies) have become available in recent years. These antibodies have been invaluable for identifying the proteinases responsible for cartilage breakdown both in vitro and in vivo. The presence of neoepitope sequences generated by specific metalloenzyme cleavage of aggrecan and type II collagen correlates well with the progression of cartilage degeneration, both in vitro and in mouse models of arthritis. Preliminary results with quantitative assays of type II collagen neoepitopes suggest that they may be useful markers of joint disease in humans. Long term studies correlating neoepitope concentration with clinical and radiographic disease are now required to validate the utility of neoepitopes as surrogate markers of cartilage degeneration and joint disease.
Insights
New biomarkers called neoepitopes show promise for tracking arthritis progression. These markers, derived from aggrecan and type II collagen breakdown, may offer a faster way to monitor joint health and therapy effectiveness.
Area of Science:
- Biochemistry
- Biomaterials Science
- Rheumatology
Background:
- Articular cartilage degradation is central to arthritis, leading to joint dysfunction.
- Current methods for monitoring cartilage health, like radiographic assessment, are slow and difficult.
- There's a need for better biomarkers to track disease progression and treatment efficacy.
Purpose of the Study:
- To explore the potential of neoepitope antibodies as biomarkers for cartilage degradation.
- To assess the correlation between neoepitope presence and arthritis progression in vitro and in vivo.
- To evaluate the utility of type II collagen neoepitopes as markers for human joint disease.
Main Methods:
- Utilized antibodies recognizing neoepitope sequences generated by proteolysis in aggrecan and type II collagen.
- Investigated the correlation between neoepitope presence and cartilage degeneration in vitro and in mouse arthritis models.
- Examined preliminary results from quantitative assays of type II collagen neoepitopes in humans.
Main Results:
- Neoepitope antibodies effectively identify proteinases responsible for cartilage breakdown.
- The presence of neoepitope sequences correlates with cartilage degeneration progression.
- Preliminary human data suggests type II collagen neoepitopes may serve as useful joint disease markers.
Conclusions:
- Neoepitope biomarkers show potential for monitoring cartilage degeneration in arthritis.
- Further long-term studies are needed to validate neoepitopes as surrogate markers for joint disease and therapy response.